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mediated through a reduction in spasm of the resistance vessels,
which is possible. Yet this does not address the obstructive effects
of atherosclerotic plaque, nor the important influence of large
artery biomechanical properties (compliance).
The suggestion that the cardiovascular effects of estrogen
therapy are mediated through antithrombotic effects is more
difficult to justify, however. To date, the only controlled interven-
tional trial based on cardiovascular outcomes is the large, well-
designed, secondary prevention Heart and Estrogen-progestin
Replacement Study (HERS) (3). Despite a wealth of previous data
suggesting individual mechanisms of cardioprotection with HRT,
no net clinical benefit was observed. Rather, an early increase in
both arterial vascular and venous thrombotic events was associated
with HRT, potentially mediated by the prothrombotic effect of
combined HRT. In keeping with this, in a recent controlled trial
of combined oral HRT, we demonstrated coagulation activation
with generation of both thrombin and fibrin (4). Although
concomitant secondary activation of fibrinolysis was observed, a
shift toward a prothrombotic state was suggested. The majority of
studies on coagulation have also noted adverse procoagulant effects
of HRT. We cannot agree that estrogen reduces the effects of
smoking by antithrombotic mechanisms, and we suggest instead
that the prothrombotic effects of estrogen may serve to neutralize
the beneficial vessel wall effects.
The results of HERS perhaps also serve to emphasise another
vital point. Although estrogen improves individual circulation
characteristics, including arterial compliance and IMT, when
studied in isolation, its effects are diverse and complex, and we
believe it is inappropriate to extrapolate from the study of isolated
mechanisms of estrogen action to the clinical implications of HRT
use. We would agree with the cautionary note expressed in the ac-
companying editorial by O’Grady that observational data should not
be overinterpreted or used alone to dictate clinical management which
should be based on definitive clinical trials. After the HERS results,
it is unlikely that other controlled trials in high risk women will be
initiated. However, a better understanding of the mechanisms of
estrogen action may assist in identifying alternative interventions,
including new selective estrogen modulating agents, with beneficial
actions on the vessel wall, without prothrombotic effects.
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Lack of Effect of Coenzyme Q
on Left Ventricular Function in
Patients With Congestive Heart Failure
The lack of benefit observed by Watson et al. (1) in patients with
advanced congestive heart failure (CHF) treated with 100 mg of
coenzyme Q 10 (CoQ 10) for three months was predictable. This is
a case of too little for too short a time and, most importantly, as the
authors postulate, too late in the course of CHF. The authors’
observations are in keeping with two previous trials similar in
design and duration of therapy.
Permanetter et al. (2) studied 25 patients with advanced idio-
pathic dilated cardiomyopathy with documented normal coronary
anatomy, using 100 mg of CoQ 10 per day for four months, in a
double-blind, crossover study design, and found a similar lack of
significant effect on measurements of myocardial function.
Hofman-Bang et al. (3) studied 79 patients, again using 100 mg of
CoQ 10 daily for three months, this time showing a very slight but
significant improvement in ejection fraction, from 23 6 12% to
25 6 13% (p , 0.05).
In contrast, in a double-blind, crossover trial, Langsjoen et al.
(4) evaluated 19 patients with idiopathic dilated cardiomyopathy
who were much earlier in the course of their disease and showed an
improvement in EF from 44 6 3% to 56 6 10% (p , 0.001) with
three months of treatment with CoQ 10, 100 mg per day.
Although the methodology for myocardial function measurements
in this early controlled trial (impedance cardiography and systolic
time indexes) has been judged “outdated” by Watson et al., the
measurements were nonetheless performed in a blinded fashion by
an experienced laboratory. The largest double-blind, controlled
trial to date by Morisco et al. (5) randomized 641 patients with
CHF to receive either placebo or 2 mg/kg body weight per day of
CoQ 10 for one year. The number of patients requiring hospital
admission for worsening heart failure was significantly lower in the
CoQ 10 group (73 vs. 118, p , 0.001), and episodes of pulmonary
edema were significantly lower (20 vs. 51, p , 0.001). Thus, a
higher dose of CoQ 10 for a longer period showed a highly
significant benefit. In a meta-analysis spanning the years of 1986 to
1995, Soja and Mortensen (6) reviewed 14 controlled trials of
patients with CHF who were treated with CoQ 10 in 60 to
200 mg/day doses as a supplement to conventional treatment.
Eight of the 14 controlled trials met the authors’ inclusion criteria
for reliable meta-analysis, with seven of the eight studies docu-
menting significant improvement in different variables of heart
function in patients with CHF of varying etiology (idiopathic
dilated cardiomyopathy, ischemic heart disease, hypertension,
valvular heart disease and congenital heart disease). Specifically,
significant improvements in stroke volume, ejection fraction,
cardiac output, cardiac index and end-diastolic volume were
observed with CoQ 10 treatment.
The findings by Watson et al. (1), Permanetter et al. (2) and
Hofman-Bang et al. (3) are in keeping with the clinical observa-
tions of cardiologists who have had extensive practical experience
with the use of this supplement in patients with advanced dilated
cardiomyopathies. The most dramatic improvements in myocar-
dial function have been observed in those patients fortunate
enough to have been treated with supplemental CoQ 10 shortly
after the diagnosis of CHF, before the development of irreversible
myocyte loss and fibrosis. Although the optimal dose of CoQ 10 in
the treatment of CHF has not been established, it has become
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clear, over the past 15 years, that 100 mg per day is suboptimal for
the majority of patients. An increase in the CoQ 10 plasma level,
in the study by Watson et al., from 903 6 345 to 2,029 6 856
nmol/liter, converts roughly to a baseline level of 0.8 mg/ml up to
a treatment value of 1.7 mg/ml. Optimal improvement in myocar-
dial function in our own patients did not occur until we attained
blood CoQ 10 levels .2.0 mg/ml, with average blood level of 2.9
mg/ml, on an average dose of 240 mg of CoQ 10 per day (7,8).
Furthermore, it has also been our observation that maximal myocar-
dial function improvement with CoQ 10 supplementation is rarely
observed at three months, but can be achieved at six to 12 months.
In summary, Watson et al. are to be commended for their
efforts, for it is a difficult, poorly funded and often thankless task
to evaluate any natural and nonpatentable substance. I am hopeful
that these investigators and others will move forward to further our
understanding of this remarkable nutrient, which, for many of us
out here in the trenches of patient care, is rapidly showing itself to
be a safe and effective addition to our therapeutic armamentarium.
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REPLY
We thank Dr. Langsjoen for his interest in our report. He believes
that treatment with 100 mg/day of coenzyme Q 10 may be
inadequate and administered too late in the course of heart failure.
In contrast, 11 of 15 studies, including his own (1), of coenzyme
Q 10 in heart failure used #100 mg/day, and all but one purported
to provide clinical benefit with this dose. He also cites uncontrolled
observations (2) that an improvement in New York Heart Asso-
ciation functional class was associated with a higher daily dose of
240 mg (range 75 to 600) and suggests that early in the course of
idiopathic dilated cardiomyopathy, patients may respond to treat-
ment with coenzyme Q 10 (3). We wonder whether the almost
normal baseline left ventricular ejection fraction of 44% of patients
early in the course of their disease raises the possibility that for
some of them myocardial dysfunction might have been transient,
perhaps due to myocarditis. We took care to ensure that our
patients had established chronic cardiac failure. Langsjoen’s group
(3) also employed 100 mg/day of coenzyme Q 10, but more
importantly, they used impedance cardiography and systolic time
indexes, measurements of left ventricular systolic function that
were perhaps appropriate 15 years ago but might now be consid-
ered imprecise and obsolete.
We agree that a large, well-conducted and long-term trial of
coenzyme Q 10 would resolve any remaining uncertainties regard-
ing the efficacy of this agent. At this time, there are no clear data
proving its therapeutic effect in heart failure. Therefore, until there
is objective contemporary evidence of improvement in myocardial
function or survival, it will remain an unproven “alternative”
therapy for patients with heart failure. Sadly, as Langsjoen points
out, it is difficult to fund and conduct large trials of a “natural and
nonpatentable substance” such as coenzyme Q 10.
Constantine Aroney
Darryl Burstow
Paul Watson
Andrew Galbraith
Gregory Scalia
Nicholas Bett
Cardiology Department
The Prince Charles Hospital
Rode Road
Chermside, Brisbane 4032
Australia
PII S0735-1097(99)00619-1
REFERENCES
1. Langsjoen PH, Langsjoen AM. Coenzyme Q 10 in cardiovascular
disease with emphasis on heart failure and myocardial ischaemia. Asia
Pac Heart J 1998;7:160–8.
2. Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Useful-
ness of coenzyme Q 10 in clinical cardiology: a long-term study. Mol
Aspects Med 1994;15 Suppl:165–75.
3. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in
classes III and IV of cardiomyopathy to therapy in a blind and crossover
trial with coenzyme Q 10. Proc Natl Acad of Sci USA 1985;82:4240–4.
Is the Lower Mortality in Patients
Treated With Aspirin and Angiotensin-
Converting Enzyme Inhibitors Due
to Decreased Norepinephrine Release?
We read with great interest the article by Leor et al. (1) supporting
the use of aspirin in patients with coronary artery disease treated
with angiotensin-converting enzyme (ACE) inhibitors. Their
study challenges the old tenet that aspirin may prevent the
cardioprotective effects of ACE inhibitors. Because ACE inhibi-
tors prolong bradykinin’s half-life, their cardioprotective effects
have been traditionally attributed to the antithrombotic and
vasodilating actions of prostacyclin released from the endothelium
by bradykinin (2). Evidence from our laboratory, however, sup-
ports the new findings of Leor et al. (1). We have recently
demonstrated that bradykinin is generated not only by the endo-
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